A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 9, 2007, Pages 1795-1800

  Woodward, M ^a,b,c   Rumley, A ^a   Welsh, P ^a   Macmahon, S ^b   Lowe, G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Coagulation; Coronary heart disease; Fibrrinolysis; Inflammation

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; INTERLEUKIN 6; LIPOPROTEIN A; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ADULT; C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY DISEASE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; INFLAMMATION; LIPOPROTEIN(A); MALE; MIDDLE AGED; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 34548106593     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02677.x     Document Type: Article

References (28)

1. Macfarlane RG. Introduction. Br Med Bull 1977; 33: 183-5.
2. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
3. Lowe GDO, Rumley A, Whincup PH, Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med 2002; 2: 429-40.
4. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study Circulation 2005; 112: 3080-7.
5. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
6. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799-809.
7. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. von Willebrand factor and coronary heart disease: Prospective study and meta analysis. Eur Heart J 2002; 23: 1764-70.
8. Danesh J, Wheeler JG, Hirshfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
9. Lowe GDO, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH. Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta analysis. Eur Heart J 2004; 25: 252-9.
10. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GDO. Fibrin D-dimer and coronary heart disease: Prospective study and meta-analysis. Circulation 2001; 103: 2323-7.
11. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
12. Lowe GDO. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemostas 2005; 3: 1618-27.
13. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
14. Lowe GDO, Rumley A, McMahon AD, Ford I, O'Reilly DStJ, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-34.
15. Lowe GDO, Sweetnam PM, Yarnell JWG, Rumley A, Bainton D, Ben-Shlomo Y. C-reactive protein, fibrin D-dimer, and risk of ischaemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-62.
16. MacMahon S, Norton R, Jackson MJ, Mackie A, Cheng S, Van der Hoorn S, Milne A, McCulloch A. Fletcher Challenge - University of Auckland Heart and Health Study: Design and baseline findings. NZ Med J 1995; 108: 499-502.
17. Woodward M. Epidemiology: Study Design and Data Analysis, 2nd edn. Boca Raton: Chapman and Hall/CRC Press, 2005.
18. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 341-53.
19. Ye Z, Liu EHC, Higgins JPT, Keavney BD, Lowe GDO, Collins R, Danesh J. Seven haemostatic polymorphisms and coronary disease: A meta analysis comprising 66155 cases and 91307 controls. Lancet 2006; 367: 651-8.
20. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J 2003; 146: 948-57.
21. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population. Edinburgh Artery Study. Circulation 2005; 112: 976-83.
22. Tzoulaki I, Murray GD, Price JF, Smith FB, Lee AJ, Rumley A, Lowe GD, Fowkes FGR. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis. Edinburgh Artery Study. Am J Epidemiol 2006; 163: 334-41.
23. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999; 104: 246-57.
24. Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R, for The International Studies of Infarct Survival (ISIS) Collaborators. Fibrinogen and coronary heart disease: Test of causality by 'Mendelian randomization'. Int J Epidemiol 2006; 35: 935-43.
25. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, Packard CJ, O'Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006; 35: 922-34.
26. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nicerkson DA, Psaty BM, Racy RP, Reiner AP. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006; 296: 2703-11.
27. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, Kilic M. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-5.
28. Greenland P, O'Malley PG. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005; 165: 2454-6.